Remove 2016 Remove Clinical Development Remove Protein Production
article thumbnail

Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

The Pharma Data

” About Elasmogen: Spun-out from the University of Aberdeen, Scotland in 2016, Elasmogen is developing soloMERs ; fully humanized (or de-immunised) VNAR, as next generation, single chain therapeutics for auto-inflammatory diseases, oncology and intracellular delivery.

article thumbnail

Beyond Steel Tanks

Codon

Once approved, patent-protected drugs are the highest-margin physical products on the planet—even with the high price of bioreactors. The real cost is clinical development. In 2012, an Israeli company called Protalix gained approval for their plant-based enzyme product for Gaucher’s disease. Why rock the boat?